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ABSTRACT
Background
Systemic lupus erythematosus (SLE) is a serious systemic autoimmune disorder that affects
multiple organ systems and is characterized by unpredictable flares of disease. Recent evidence
indicates a role for type I interferon (IFN) in SLE pathogenesis; however, the downstream effects
of IFN pathway activation are not well understood. Here we test the hypothesis that type I IFN-
regulated proteins are present in the serum of SLE patients and correlate with disease activity.
Methods and Findings
We performed a comprehensive survey of the serologic proteome in human SLE and
identified dysregulated levels of 30 cytokines, chemokines, growth factors, and soluble
receptors. Particularly striking was the highly coordinated up-regulation of 12 inflammatory
and/or homeostatic chemokines, molecules that direct the movement of leukocytes in the
body. Most of the identified chemokines were inducible by type I IFN, and their levels
correlated strongly with clinical and laboratory measures of disease activity.
Conclusions
These data suggest that severely disrupted chemokine gradients may contribute to the
systemic autoimmunity observed in human SLE. Furthermore, the levels of serum chemokines
may serve as convenient biomarkers for disease activity in lupus.
The Editors’ Summary of this article follows the references.
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Systemic lupus erythematosus (SLE, also called lupus) is a
chronic, inﬂammatory autoimmune disease characterized by
nuclear autoantibodies, immune complex formation, and
systemic vasculitis [1]. Organs targeted in SLE include the
skin, joints, lungs, blood cells, kidneys, and the central and
peripheral nervous systems. The disease affects 0.1% of the
population and shows a striking 9:1 female predominance.
The factors contributing to the onset and progression of SLE
are not well understood; however, genetic, environmental,
and hormonal inﬂuences clearly contribute. SLE is difﬁcult to
diagnose, and the disease course is characterized by un-
predictable ﬂares and remissions. Thus, there is a pressing
need to develop biomarkers that will allow for more accurate
diagnoses and facilitate better assessment of disease activity
and organ involvement.
Recently, we, and others, have used gene expression
microarrays to discover a group of interferon (IFN)-regulated
mRNA transcripts that are expressed at elevated levels in the
blood cells of most SLE patients [2–4]. The IFNs are a family
of cytokines originally identiﬁed on the basis of their ability
to mediate cellular resistance to viral infection [5]. They
inﬂuence cell proliferation, differentiation, and survival of
mature lymphocytes, class switching at immunoglobulin
heavy chain loci and activation of dendritic cells (DCs), and
have a central role in host defense against infections and
tumorigenesis [6]. The type I IFNs consist of 13 IFN-a
subtypes, IFN-b, and IFN-X, which act through the same two-
subunit receptor (IFNAR1 and IFNAR2) [6]. Type I IFNs are
induced by viruses, bacteria, and synthetic compounds such
as double-stranded RNA and imiquimod, and are produced
mainly by plasmacytoid DCs and macrophages. Type II IFN,
IFN-c, acts through distinct receptor subunits (IFNGR1 and
IFNGR2) and is produced by T, natural killer, and natural
killer T cells in response to T cell receptor stimulation and
cytokines.
In addition to the recent gene array ﬁndings in SLE [2–4],
there is a growing body of evidence linking type I IFN and
lupus pathogenesis. About 20% of human patients treated
with IFN-a developed positive blood tests for anti-nuclear
antibodies, and there are case reports of individuals treated
with IFN-a going on to develop SLE (reviewed in [7]). Elevated
levels of serum IFN-a are detectable in human SLE patients
[8], and these levels are sufﬁcient to induce the maturation of
normal monocytes into activated DCs [9]. Type I IFN pathway
activation in SLE may result, in part, from the triggering of
intracellular toll-like receptors (TLR7 and TLR9) expressed
in plasmacytoid DCs by nucleic acid-containing immune
complexes [7]. Genetic variation in toll-like receptor signal-
ing pathways, such as recently shown for IRF5 [10], is also
likely to be important for SLE pathogenesis. The ability of
IFN-a to stimulate differentiation of B cells to antibody-
secreting plasma cells [11] suggests the possibility of a feed-
forward cycle contributing to disease. Here we report the
results of a comprehensive analysis of serum proteins in SLE.
Methods
Research Participants, Samples, and Clinical Data
SLE patients were enrolled from the Hopkins Lupus
Cohort [12] under the auspices of the National Institutes of
Health/National Institute of Arthritis and Musculoskeletal
and Skin Diseases-Sponsored Autoimmune Biomarkers Col-
laborative Network, following informed consent. Healthy age-
and gender-matched controls were recruited at the Univer-
sity of Minnesota (Minneapolis, Minnesota, United States).
Blood was collected by peripheral venipuncture and the sera
separated in serum-separator Vacutainer tubes (Becton-
Dickinson, Palo Alto, California, United States). A protease
inhibitor (aprotinin, 1 lg/ml) was added to each sample, and
aliquots were immediately frozen at  80 8C.
Whole blood gene expression proﬁles were obtained on
blood collected concurrently using the PaxGene system
(Qiagen, Valencia, California, United States/Becton-Dick-
inson, Franklin Lakes, New Jersey, United States). cRNA
probes were generated from PaxGene RNA and hybridized
with Affymetrix U133A chips (Santa Clara, California, United
States) using standard protocols. The levels of 82 IFN-
regulated genes that distinguish SLE from controls were
normalized and used to assign a gene expression ‘‘score,’’ as
described [2]. Fifteen patients with the highest up-regulation
of IFN-regulated transcripts (IFN-hi) and 15 patients with
lower levels of the same transcripts (IFN-lo) were studied, in
addition to 15 healthy controls selected randomly from a
larger collection of age- and gender-matched controls.
Detailed clinical data were available for each visit and
included the disease activity measures SLE Disease Activity
Index (SLEDAI) and Systemic Lupus Activity Measure,
laboratory test results, and medication proﬁles. The SLEDAI
[13] consists of 22 deﬁned, weighted items grouped into nine
organ systems. The index is calculated by summing all
weighted items that were present within the previous ten
days. Possible SLEDAI scores range from 0 to 101. The
Systemic Lupus Activity Measure-Revised (SLAM-R) lists 33
clinical and laboratory manifestations of SLE [14]. Each
manifestation is graded according to the severity of activity
within the month before evaluation. Possible total scores
range from 0 to 86.
Serum Protein Measurements
The levels of 160 serum protein analytes were measured in
serum aliquots (100 ll) from the cases and controls using
custom dual-antibody sandwich immunoassay arrays, as
described (Table S1) [15,16]. Brieﬂy, monoclonal capture
antibodies speciﬁc for each analyte were ﬁxed to glass slides,
with 12 replicate spots for each analyte. Duplicate samples of
sera were incubated for 2 h and then washed. Slides were then
incubated with secondary biotinylated polyclonal antibodies,
and signals were ampliﬁed using a ‘‘rolling circle’’ method
[16]. Quality control measures included optimization of
antibody pairs, the use of internal controls to minimize
array-to-array variation, and standardized procedures of chip
manufacturing [15,16]. Arrays were scanned using a Tecan
LS200 (Tecan, Ma ¨nnedorf, Switzerland) and mean ﬂuores-
cence intensities were generated with customized software.
To convert mean ﬂuorescence intensities to concentration
values, 15 serial dilutions of recombinant analytes at known
concentrations were used to develop best-ﬁt equations for
each analyte. Four anchor-point control dilutions of re-
combinant analytes were included on each slide. The upper
and lower limits of quantitation were deﬁned to ensure a
dynamic working range. An additional 12 analytes were
measured on the protein microarrays (beyond the 160) for
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limits of detection; these were excluded from further analysis
(Table S1).
In order to validate a subset of the results obtained from
the microarray platform, we measured the levels of two of the
chemokines, CCL2 (MCP-1) and CXCL9 (MIG), in 40 serum
samples (15 IFN-hi, 12 IFN-lo, and 13 controls) using
Biosource, Protein Multiplex Immunoassays (Invitogen,
Carlsbad, California, United States) coupled with Luminex
xMAP technology (Luminex, Austin, Texas, United States).
Samples were run in duplicate, and calibrated recombinant
proteins were used to generate standard curves. The
coefﬁcient of variance for duplicates averaged 10.7%. Linear
regression was used to calculate correlation coefﬁcients
between the results obtained on the microarray platform
and the Luminex assays after the data had been log2
transformed. These analyses indicated a high level of
concordance between the two platforms (Figure S1). CXCL10
(IP-10) was not included on the antibody microarray panel,
and levels were measured by Luminex assays.
In Vitro Type I IFN Stimulations
Peripheral blood mononuclear cells (PBMCs) from healthy
donors were isolated using lymphocyte separation medium
(Mediatech Cellgro, Herndon, Virginia, United States).
PBMCs were resuspended in complete medium (RPMI 1640
consisting of 2 mM L-glutamine, 50 units/ml penicillin, and 50
lg/ml streptomycin) þ 10% autologous plasma at 2 million
cells/ml. Cells were incubated in medium alone or with 1,000
units/ml each IFNa and IFNb (R & D Systems, Minneapolis,
Minnesota, United States) for 6 or 24 h, and total RNA was
isolated and converted to cRNA (Ambion, Austin, Texas,
United States), which was then hybridized to Affymetrix
U133A gene expression arrays and analyzed using Microarray
Suite 5.0. Transcripts were considered IFN-regulated if there
was a mean change in expression of greater than 2-fold when
compared to PBS control at either 6 or 24 h, together with a
difference in expression of greater than 500 Affymetrix
expression units as compared to control incubations.
Statistical Methods
Clinical features of the IFN-hi and IFN-lo groups were
compared using Student’s unpaired t-test for continuous
variables or the Fisher’s exact test for binary data. The levels
of individual analytes were compared between the IFN-hi,
IFN-lo, and control sample groups using Student’s unpaired
t-test. Analyte levels and continuous clinical variables gen-
erally followed a normal distribution. To conﬁrm the results
generated by t-tests we used the nonparametric Mann-
Whitney test (Table S1). Corrections for multiple testing
were performed using the method of Benjamini and Hoch-
berg (Table S1) [17]. Also, one-way ANOVA was used to
conﬁrm results from pairwise t-tests (Table S1). Concen-
tration values for each analyte of interest were normalized to
the mean of controls, log2 transformed, and then subjected to
unsupervised hierarchical clustering (CLUSTER) and visual-
ized using TreeView [18] (both programs can be downloaded
free of charge at the Web site of Michael Eisen: http://rana.lbl.
gov/EisenSoftware.htm).
The levels of seven IFN-regulated chemokines—CCL2
(MCP-1), CCL3 (MIP-1a), CCL8 (MCP-2), CCL19 (MIP-3b),
CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC)—were
used to calculate a ‘‘chemokine score.’’ Concentration values
were normalized across all samples so that the maximum
value for any analyte was 1.0, and values for each sample were
then summed to derive the ﬁnal score.
Clinical data including disease activity indices (SLEDAI,
SLAM-R) and laboratory results (anti-DNA antibodies,
complement levels, erythrocyte sedimentation rates [ESR],
white blood cell [WBC] counts, and hematocrit) were
compared with analyte data using linear regression analysis
(Pearson’s correlation). One of the IFN-lo cases had insufﬁ-
cient clinical data and was excluded from the regression
analyses. To determine the statistical signiﬁcance of each
comparison, random permutation analysis was performed to
deﬁne the p-value thresholds.
To assess the possible role of chemokines in organ-speciﬁc
disease involvement, we identiﬁed those patients who showed
evidence for active disease as determined by the organ
speciﬁc features of the Physician’s Global Assessment,
SLEDAI, and SLAM-R, or by laboratory testing. The patient
group was then divided into two groups (positive and
negative), and Student’s unpaired t-tests were used to
compare chemokine levels between the groups.
Results
In an effort to build upon our recent gene expression
studies of peripheral blood cells [2], we used a novel high-
throughput protein microarray platform [15,16] to measure
the levels of 160 analytes in blood serum of SLE cases and
controls. Two groups of SLE cases were studied. The ﬁrst
demonstrated high levels of IFN-regulated mRNA transcripts
(IFN-hi) in whole blood as determined by gene expression
arrays, while the second group had low levels of these
transcripts (IFN-lo), similar to those of controls (Figure 1).
Table 1 compares the clinical and demographic features of
the two groups. The IFN-hi group was enriched for African-
American women (8/15) compared with the IFN-lo group (2/
15; p ¼ 0.05) and, on average, fulﬁlled more criteria for SLE
(7.3) than IFN-lo cases (5.7; p ¼ 0.004). All of the IFN-hi cases
had a history of positive anti-dsDNA antibodies and either
Figure 1. IFN Gene Expression Scores for IFN-hi SLE, IFN-lo SLE, and
Control Participants
Whole blood gene expression microarrays were used to identify 82 type I
IFN-regulated genes that distinguished 81 SLE cases from 42 controls.
From these genes, a normalized IFN gene score was derived. Plotted are
IFN gene scores for 15 IFN-hi SLE (mean 6 SD, 41.0 6 4.8), 15 IFN-lo SLE
(14.4 6 2.8), and 15 controls (12.1 6 1.9).
doi:10.1371/journal.pmed.0030491.g001
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found in only about half of the IFN-lo group. The IFN-hi
group also showed evidence of more active disease than the
IFN-lo group as determined by higher SLEDAI and SLAM-R
scores, together with several laboratory measures character-
istic of active disease (low complement C3 and elevated ESR
and anti-double-stranded DNA antibodies) at the time of the
visit. There were no signiﬁcant differences in medication
proﬁles between the groups. Thus, similar to our earlier
observations in an independent cohort of SLE cases [2],
disease severity appears to be increased in IFN-hi as
compared to IFN-lo patients.
Of the 160 analytes measured, 30 (19%) showed signiﬁcant
differences in serum levels in at least one intergroup
comparison (Figure 2). All 30 analytes were different between
the IFN-hi SLE group and controls, and most varied between
IFN-lo SLE and controls. Surprisingly, expression levels for
most of the analytes (19/30 [63%]) were not signiﬁcantly
different between IFN-hi and IFN-lo SLE. The majority of
analytes identiﬁed (23/30 [77%]) exhibited higher serum
levels in one or more of the SLE groups compared to
controls. Notably, the levels of most CD4þ T helper-1 (TH1)
cytokines (interleukin [IL]-2, TNF-a, and IFN-c) and T helper-
2 (TH2) cytokines (IL-4, IL-9, IL-10, and IL-13) were similar in
both SLE and control groups (Table S1).
Down-regulated analytes included IFN-X, angiotensin
converting enzyme, angiotensin converting enzyme-2, the
chemotactic cytokine (chemokine) CCL20 (MIP-3A), the
growth factor FGF-2, and soluble growth factor receptors
(FGF-R3, PDGF-RA). Up-regulated analytes included several
cytokines (IL-5, IL-6, IL-15, IL-18, BDNF, and GDNF), the
cytokine receptors IL-2SRA and TGF-B RIII, matrix metal-
loproteinase 7, and the adhesion molecule ICAM-3. Strik-
ingly, 12 of the 23 up-regulated analytes identiﬁed were
chemokines and included representatives of both the CC- and
CXC- families [19]. Chemokines are an important group of
Table 1. Clinical and Demographic Features of SLE Cases
Catergory Feature IFN-hi (n ¼ 15) IFN-lo (n ¼ 15) p-Value
General Age (average) 37.7
a 40.9 NS
Female 15
b 13 NS
Caucasian 6 13 0.01
African American 8 2 0.05
Historical ACR criteria (average number) 7.3 5.7 0.004
Malar rash 11 7 NS
Discoid rash 3 1 NS
Photosensitivity 8 6 NS
Oral/nasal ulcers 8 9 NS
Arthritis 12 12 NS
Pleurisy/pericarditis 13 7 0.03
Renal 9 8 NS
Neurologic 3 0 NS
Hematologic 14 12 NS
Immunologic 15 8 0.003
Positive anti-nuclear antibodies 15 15 NS
History of low C3 15 7 0.001
History of low C4 14 6 0.003
History of anti-dsDNA antibodies 15 8 0.003
History of anti-Ro antibodies 8 3 NS
History of anti-La antibodies 4 0 0.05
Current visit Physician’s Global Assessment (0–3 scale) 1.5 1.1 NS
SLEDAI 5.6 2.3 0.008
British Isles Lupus Aseessment Group 4.8 3.9 NS
SLAM-R 5.9 2.8 0.0001
Hematocrit 37.3 36.9 NS
WBC count 5.3 7.4 NS
ESR 51.3 19.7 0.008
Complement C3 80.5 109.6 0.008
Complement C4 13.9 18.6 NS
Positive anti-DNA antibodies 8 1 0.007
Platelet count 264.4 181.7 NS
Lymphocyte count 0.8 1.6 0.013
Medications Prednisone (average dose, mg) 13 (14.6) 9 (21.9) NS
Intravenous steroids 6 4 NS
Immunosuppressives 4 7 NS
Steroids and/or immunosuppressives 14 11 NS
Plaquenil 12 12 NS
NSAIDs 6 4 NS
aContinuous variables were compared using unpaired t-tests and results reported with one decimal place.
bData indicate the number of individuals positive for the feature within each group of 15. These variables were compared using Fisher’s exact test.
NS, not significant.
doi:10.1371/journal.pmed.0030491.t001
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inﬂammatory sites and guide the homeostatic movement of
immune cells to speciﬁc subregions of secondary lymphoid
tissues [20]. Most of the chemokines identiﬁed are inducible
by type I IFN (highlighted in red in Figure 2, and see Figure 3
below). Seven of the 11 analytes that differed in serum levels
between IFN-hi and IFN-lo SLE cases were IFN-regulated
chemokines.
Hierarchical clustering analysis showed that many of these
proteins were coordinately dysregulated in the serum of a
large percentage of IFN-hi patients and in a smaller fraction
of IFN-lo cases (Figure 3). The left-hand portion of Figure 3
show the results of 6 and 24 h stimulations of normal control
PBMCs with type I IFN in vitro and identify analytes that were
transcriptionally regulated by type I IFN as determined by
gene expression arrays. From these data we conclude that
many SLE patients are in an IFN-regulated chemokine
‘‘storm,’’ with broad dysregulation of serum protein proﬁles.
Furthermore, the highest levels of IFN-inducible analytes are
found in patients carrying the IFN blood cell gene signature.
For the majority of individual analytes, there was a very
poor correlation between the levels of gene expression
observed in blood and their protein levels in serum (Figure
S2). In contrast, the IFN-regulated chemokine protein levels
were generally highly correlated with the presence of IFN-
responsive gene transcripts in blood (IFN gene ‘‘score’’)
(Figure 4). The discordance between chemokine protein and
mRNA levels in blood may reﬂect the short half-life of
chemokine and cytokine mRNAs or, alternatively, may
indicate that the primary sites of chemokine production are
extra-vascular. The latter seems likely, given that many
chemokines are synthesized locally in tissues in response to
inﬂammatory stimuli, transcytosed through vascular endo-
thelial cells lining venules and capillaries [21], and then
presented on the luminal surface of vessels for interaction
with rolling leukocytes.
Figure 2. Thirty Protein Analytes Dysregulated in SLE Serum
Sera from 15 IFN-hi SLE, 15 IFN-lo SLE, and 15 controls were assayed for the presence of 160 protein analytes by antibody microarrays. CXCL10 (IP-10)
was measured by Luminex bead immunoassays. Shown are 30 analytes that demonstrated significant differences in at least one inter-group
comparison, using the following criteria: mean fold change (FC)   1.5, and p , 0.05 by unpaired t-test. Data are presented as mean fold change of the
group comparisons. Analytes regulated by type I IFN, as determined by in vitro gene expression microarray experiments, are highlighted in red font. * p
, 0.05; ** p , 0.01; *** p , 0.001; **** p , 0.0001; ***** p , 0.00001. Comparisons highlighted in yellow represent significant positive associations, and
blue indicates significant negative associations. The levels of statistical significance shown represent nominal p-values and are not corrected for the
multiple hypotheses tested. The results obtained when these p-values were corrected using the Benjamini-Hochberg adjustment for multiple testing
are provided in Table S1.
doi:10.1371/journal.pmed.0030491.g002
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tions with clinical measures of disease activity (Figure 4).
Many of the IFN-regulated analytes showed strong positive
correlations with the SLEDAI [13] and the SLAM-R [14], two
validated measures of global disease activity, as well as with
the ESR and titers of anti-dsDNA antibodies. The IFN-
regulated analytes were negatively correlated with hematocrit
and complement C3 levels and showed similar negative trends
with complement C4 levels and WBC counts.
An IFN-regulated chemokine protein ‘‘score,’’ derived
from the normalized levels of seven analytes, reﬂected the
trends observed with the individual IFN-inducible analytes
and showed stronger associations than any single analyte
(Figure 4). The data also suggest that the chemokine score is
more highly correlated with disease activity, as measured by
SLEDAI, SLAM-R, ESR, and anti-DNA antibodies, than the
IFN gene score for these individuals (Figure 4). We conclude
that there are striking clinical correlations of many analytes,
especially those that are IFN-regulated, with various measures
of SLE disease activity.
We next asked whether the chemokine levels measured in
serum were correlated with speciﬁc organ system involve-
ment. We divided the patients on the basis of the presence or
absence of organ system disease activity at the time of the
visit (renal, serositis, hematologic, and skin) and then
compared levels of individual chemokines (Tables 2 and S2).
CXCL11 (I-TAC), CXCL13 (BLC), CXCL10 (IP-10), and CCL3
(MIP-1A) were present at signiﬁcantly higher levels in serum
of patients with active renal disease than those without.
Levels of CCL8 (MCP-2), CCL2 (MCP-1), and CXCL2 (GROB)
trended towards signiﬁcance. The overall chemokine score
was also elevated in patients with renal disease as compared
to those without (Table 2).
Higher levels of CCL17 (TARC), CXCL10 (IP-10), and CCL2
(MCP-1) were found in the small subset of patients (n¼4) with
active serositis. Interestingly, a negative correlation was
observed between levels of CCL20 (MIP-3A), CCL17 (TARC),
Figure 3. Coordinate Dysregulation of Serum Protein Levels in SLE
Hierarchical clustering was applied to protein levels of the identified analytes (‘‘Serum Protein Levels’’). Individual data points represent the log2 ratio of
the analyte concentration to the mean of control concentrations (scale shows linear fold-differences). ‘‘In Vitro Control PBMC Gene Expression’’ columns
present gene expression microarray data obtained by incubating normal control PBMCs in vitro with medium alone or with type I IFN for 6 and 24 h.
Data are normalized to control medium-alone conditions (scale depicts linear fold-differences). Grey boxes indicate missing data. Analytes induced by
type I IFN in vitro (.2-fold and .500 expression unit mean difference) are highlighted in red font.
doi:10.1371/journal.pmed.0030491.g003
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system involvement (mostly thrombocytopenia) (Table 2), and
several additional chemokines (CXCL13 [BLC], CCL3 [MIP-
1a], and CXCL11 [I-TAC]) trended towards signiﬁcance. No
signiﬁcant correlations were observed for patients with skin
disease (Table S2). In a reciprocal approach, we ranked the 30
patients by serum levels of individual chemokines, divided
each group evenly into chemokine ‘‘X’’ high and low groups,
and compared clinical features (Figure S3). These data
generally mirrored the ﬁndings shown in Table 2 and
demonstrated that many chemokines were associated with
nephritis in this sample, and that lower chemokine levels
were generally observed in individuals with hematologic
involvement.
Discussion
Using a comprehensive protein microarray survey of the
serologic proteome, we identiﬁed 30 dysregulated protein
analytes in SLE, the majority of which were not previously
implicated in systemic lupus. Furthermore, we demonstrate
that SLE patients carrying the IFN gene signature are at
particular risk for a dramatic coordinate dysregulation of
IFN-responsive cytokines and chemokines in serum, and this
pattern is strongly associated with various measures of disease
activity. We hypothesize that high levels of systemic chemo-
kines in active SLE, driven by type I IFN, lead to a state of
‘‘chemokine confusion’’ that alters the normal trafﬁcking and
chemotaxis of leukocytes in the body, setting the stage for
widespread, systemic autoimmunity. High-level production of
chemokines may also contribute to human SLE by recruiting
immune and inﬂammatory cells into target tissues and by
impairing the normal localization of certain populations of
immune cells in the body, perhaps through chemokine
receptor desensitization [22].
An interesting ﬁnding of this study is the similarity of
cytokine/chemokine proﬁles between IFN-hi and IFN-lo SLE
cases (Figures 2 and 3), including elevated levels of many IFN
regulated analytes in IFN-lo serum. There are several
potential explanations for these ﬁndings. First, IFN-lo
patients may have stimuli other than type I IFN driving
cytokine and chemokine expression, although we believe this
to be unlikely. Second, the production of type I IFN in IFN-lo
patients may be highly localized to tissues or secondary lymph
organs, such that the gene expression ‘‘footprints’’ of
interferon stimulation are not measurable in the blood of
these patients. Third, IFN-lo patients may produce lower
levels of type I interferon that are sufﬁcient to induce IFN-
responsive chemokines and cytokines, but insufﬁcient to
result in a strong IFN gene expression signature in blood
cells. Regardless of the precise mechanism, the data suggest
that type I interferon may be contributing to the patho-
genesis of SLE in the majority of adult patients, as previously
shown for pediatric SLE [3].
These data conﬁrm previous studies reporting elevated
levels of IL-6 [23], IL-15 [24], IL-18 [25], and the soluble IL-2
receptor alpha [26] in SLE serum. Interestingly, classically
deﬁned TH1 and TH2 cytokines such as IFN-c, IL-2, IL-4, IL-
Figure 4. IFN-Regulated Chemokines Are Associated with SLE Disease Activity
Shown are 20 serum analytes that exhibited significant positive (highlighted in yellow) or negative (highlighted in blue) correlation coefficients with
clinical measures of SLE. The IFN gene score was calculated from 82 IFN-inducible transcripts measured by concurrent whole blood gene expression
microarrays. The chemokine protein ‘‘score’’ was calculated using the seven IFN-regulated CC and CXC chemokines highlighted in red. * p , 0.05; ** p
, 0.01; *** p , 0.001; **** p , 0.0001. p-Values were obtained by permutation testing.
doi:10.1371/journal.pmed.0030491.g004
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levels between SLE and controls (see Table S1). Although
many studies have explored the TH1/TH2 paradigm in SLE
[27], there is no dominant consensus as to how TH1/TH2
pathways contribute to SLE. The lack of skewing of TH1/TH2
cytokines in the current study suggests either that this
paradigm is not a deﬁning feature of systemic lupus, or that
measurement of these cytokines in serum is not a sensitive
gauge of the status of these pathways in SLE.
Our conclusion that IFN-regulated chemokines are impor-
tant in SLE disease pathogenesis is supported by a number of
reports in the literature. Early studies suggested that serum
and urine levels of CCL2 (MCP-1) [28,29] and CXCL8 (IL-8)
[30,31] were associated with active lupus nephritis. A recent
report by Rovin et al. [32] showed that CCL2 (MCP-1) levels in
urine are a much better marker for ﬂares of renal disease
than CXCL8. Surface levels of CCR4, the receptor for CCL17
(TARC), are elevated on CD4þ T cells in active SLE [33], and
lupus nephritis biopsies show high numbers of inﬁltrating
CCR4þ T cells [34]. Other studies in SLE have described
elevated serum levels of CCL5 (RANTES) [35], CXCL10 (IP-
10) [36], the chemokine fractalkine [37], and CXCL9 (MIG)
[38] in SLE, with levels often correlating with disease activity.
Recent studies in cutaneous lupus erythematosus (CLE) also
suggest an important role for chemokines and their receptors
in mediating autoimmune skin inﬂammation. The chemo-
kines CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC)
and the type I IFN-inducible intracellular protein MxA were
found at elevated levels in skin lesions of CLE patients [39,40],
and these sites were also enriched for CXCR3þT cells [39,40],
while the blood was relatively depleted [40]. CCL17 (TARC)
and T cells bearing the CCR4 receptor were also found in the
epidermis of CLE cases [41].
The current data demonstrate, to our knowledge for the
ﬁrst time, the coordinated up-regulation of IFN-regulated
chemokines and cytokines in SLE and clearly link the
expression of many of these analytes to the IFN gene
signature. Together, these data suggest that the targeting of
T cell-dependent autoimmune responses to various SLE end
organs (e.g., kidney, skin, pleura, and central nervous system)
may be mediated by local production of IFN-responsive
chemokines. CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-
TAC) were present at elevated levels in SLE serum and are
known to recruit CXCR3þ effector and memory T cells, as
well as natural killer cells and a subset of plasma cells to
inﬂammatory sites. CCL2 (MCP-1), CCL3 (MIP-1a), CCL7, and
CCL8 (MCP-2) are chemotactic for T cells and DCs, and may
additionally contribute to systemic inﬂammation. The clinical
observation that patients with active systemic lupus are often
leukopenic may be related to chemokines driving lympho-
cytes out of the vascular space, as suggested for CXCR3þ T
cells in CLE [40]. The negative correlations between WBC
counts and IFN-regulated chemokine levels lend further
support for this idea (Figure 4).
High serum and tissue levels of chemokines are known to
desensitize immune cells to the normal chemotactic action of
endothelial chemokines or tissue gradients [22]. In mice,
systemic overexpression of MCP-1 impaired the ability of
monocytes to home to a localized MCP-1 gradient [42]. This
mechanism could explain the unusual presence of antibody
secreting plasmablasts and plasma cells in the blood of SLE
patients [43], a situation that is generally not observed in
healthy individuals due to the normal homing of plasma cells
along CXCL12 (SDF-1) gradients to the bone marrow [44].
Another possible consequence of the chemokine ‘‘storm’’ is
impaired recruitment of Foxp3þ T regulatory cells to
inﬂammatory sites. T regulatory cells suppress ongoing
autoimmune responses, and their recruitment depends on
interactions between CCR4 and its ligand CCL22 [45]. We
show here that CCL17 (TARC), an alternate ligand for CCR4,
Table 2. Chemokine Levels and Clinical Features of SLE
Manifestation Analyte Mean 6 SD, Positive Mean 6 SD, Negative Mean Fold Change (Positive/Negative) p-Value
Renal
a CXCL11 (I-TAC) 288 6 196 162 6 67 1.77 0.014
Chemokine score 2.7 6 1.5 1.7 6 0.7 1.56 0.022
CXCL13 (BLC) 289 6 191 169 6 101 1.71 0.032
CXCL10 (IP-10) 127 6 127 52 6 59 2.43 0.045
CCL3 (MIP-1A) 429 6 147 340 6 87 1.26 0.047
CCL8 (MCP-2) 52 6 37 32 6 19 1.63 0.057
CCL2 (MCP-1) 136 6 148 71 6 56 1.92 0.090
CXCL2 (GROB) 1322 6 933 742 6 824 1.78 0.093
Serositis
b CCL17 (TARC) 128 6 107 59 6 40 2.16 0.019
CXCL10 (IP-10) 172 6 179 61 6 61 2.84 0.023
CCL2 (MCP-1) 175 6 181 80 6 79 2.21 0.070
Hematologic
c CCL20 (MIP-3A) 67 6 98 3 6 15 0.81 0.013
CCL17 (TARC) 26 6 13 81 6 58 0.33 0.020
CXCL2 (GROB) 332 6 220 1119 6 937 0.30 0.038
CXCL8 (IL-8) 5 6 21 0 6 6 0.50 0.038
CXCL13 (BLC) 120 6 19 237 6 157 0.51 0.062
CCL3 (MIP-1A) 302 6 72 390 6 120 0.77 0.076
CXCL11 (I-TAC) 128 6 28 227 6 147 0.56 0.089
Chemokine score 1.4 6 0.4 2.3 6 1.2 0.64 0.095
aPositive, n ¼ 10; negative, n ¼ 20.
bPositive, n ¼ 4; negative, n ¼ 26.
cPositive, n ¼ 7; negative, n ¼ 23.
doi:10.1371/journal.pmed.0030491.t002
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Interferon-Regulated Chemokines and SLEis up-regulated in many SLE patients, and we speculate that
this may lead, via receptor desensitization, to impaired
chemotaxis of T regulatory cells into autoimmune inﬂamma-
tory sites. Elevated levels of the homeostatic chemokine
CXCL13 (BLC), which targets CXCR5þB cells to follicles, and
CCL19 (MIP-3b), which directs T cells, B cells, and DCs into
the T cell zones of secondary lymph tissue, could also mediate
ectopic lymphoid aggregates or germinal centers in non-
lymphoid tissues [46]. Another potential result of elevated
chemokine levels in SLE is heightened costimulatory signal-
ing for T cells during cognate interactions with antigen-
presenting cells [47]. Overall, the correlations between
chemokine levels and organ system involvement observed in
the current study are extremely complex (Tables 2 and S2),
and additional work will be required with an increased
sample size to understand how individual chemokines are
contributing to speciﬁc organ inﬂammation in SLE.
Other analytes identiﬁed in this screen are also likely
contributing to the widespread immune activation observed
in SLE. Matrix metalloproteinase 7 has been shown to
participate in the establishment of chemokine gradients at
mucosal surfaces [48]. IL-6 is a major positive regulator of B
cell differentiation into plasma cells, and IL-15 and sIL-2R
function to control the proliferation of T cells. Major
challenges for the future will be to determine how these
soluble mediators synergize for the induction and main-
tenance of autoimmune responses in SLE, to further explore
the relationship between the unique cytokine and chemokine
milieu present in individual patients, and the profound
clinical heterogeneity characteristic of SLE.
In conclusion, this study provides new perspective on the
nature and extent of the immune dysregulation in lupus and
lends further support for a central role of type I IFN in SLE
pathogenesis. The data indicate that monitoring chemokine
levels in blood of lupus patients may be useful clinically in
assessing lupus disease activity. Finally, these ﬁndings suggest
that new therapies aimed at blocking type I IFN or chemokine
action may be effective in SLE.
Supporting Information
Figure S1. Measurement of CCL2 (MCP-1) and CXCL9 (MIG) Using
Luminex Bead-Based Immunoassays
Linear regression analysis comparing the results obtained using the
protein antibody microarrays and Luminex bead immunoassays for
the analytes CCL2 (MCP-1; r ¼ 0.91) and CXCL9 (MIG; r ¼ 0.8) after
the data were log2 transformed. Units are pg/ml.
Found at doi:10.1371/journal.pmed.0030491.sg001.
Figure S2. Weak Correlation Between Serum Protein Levels and
Blood Gene Expression Levels
Linear regression analysis was used to measure the correlations of
individual protein levels with concurrent gene expression levels in
whole blood for the patient and control groups as determined by
Affymetrix microarrays. Dotted lines indicate p , 0.05 thresholds.
Analytes regulated by type I IFN are highlighted in red font.
Found at doi:10.1371/journal.pmed.0030491.sg002.
Figure S3. Incidence of Organ System-Speciﬁc Disease Involvement
in Patient Groups Divided by Serum Chemokine Levels
For each chemokine, patients were segregated into two groups of 15
(chemokine ‘‘X’’ Hi, chemokine ‘‘X’’ Lo) based on serum chemokine
concentrations (pg/ml). Bar graphs represent the incidence of lupus
disease manifestations (skin, serositis, renal, and hematologic involve-
ment) at the time of the visit. Fisher’s exact test was used to determine
p-values. * p , 0.05; ** p , 0.01.
Found at doi:10.1371/journal.pmed.0030491.sg003.
Figure S4. Chemokine Protein Scores
Chemokine scores were calculated as described in the Methods
section and are plotted for 15 IFN-hi SLE (mean 6 standard
deviation [SD], 2.8 6 1.2), 15 IFN-lo SLE (1.4 6 0.5), and 15 controls
(1.0 6 0.2).
Found at doi:10.1371/journal.pmed.0030491.sg004.
Table S1. Mean Serum Concentrations for 161 Analytes
Mean serum analyte concentrations (pg/ml) for 15 IFN-hi SLE cases,
15 IFN-lo SLE cases, and 15 controls.
Found at doi:10.1371/journal.pmed.0030491.st001.
Table S2. Serum Chemokine Levels and Organ System Involvement
Serum chemokine levels (pg/ml) and speciﬁc SLE organ system
involvement at the time of the visit.
Found at doi:10.1371/journal.pmed.0030491.st002.
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Background. The term ‘‘lupus,’’ meaning wolf in Latin, is often used as
an abbreviation for the disease systemic lupus erythematosus (SLE). The
name may have been given because some people with SLE have a rash
that slightly resembles a wolf’s face. The condition affects around 50 to
100 people per 100,000, and is much more common in women than
men. SLE is a complicated disease that comes about when antibodies
inappropriately attack the body’s own connective tissues, although it is
not known why this happens. Symptoms vary between different people;
the disease may get better and then worse, without explanation; and can
affect many different organs including the skin, joints, kidneys, blood
cells, and brain and nervous system. SLE is difficult for doctors to
diagnose. Although the disease cannot be cured, patients who are
diagnosed with SLE can be treated for their symptoms, and the right
management can slow progress of the disease. One area of SLE research
focuses on finding ‘‘molecular markers’’ (e.g., proteins or other
compounds) that could be tested for in the blood. Researchers hope
this would help doctors to more accurately diagnose SLE initially, and
then also help to track progress in a patient’s condition.
Why Was This Study Done? ‘‘Gene expression’’ is a term meaning the
process by which a gene’s DNA sequence is converted into the structures
and functions of a cell. These investigators had found in previous studies
that certain genes were more ‘‘highly expressed’’ in the blood cells of
patients with SLE. Some of these genes were already known to be
regulated by interferons (a group of proteins, produced by certain blood
cells, that are important in helping to defend against viral infections). The
investigators performing this study wanted to understand more clearly
the role of interferon in SLE and to see whether the genes that are more
highly expressed in patients with SLE go on to produce higher levels of
protein, which might then provide useful markers for monitoring the
condition.
What Did the Researchers Do and Find? This research project was a
‘‘case-control’’ study, in which the researchers compared the levels of
certain proteins in the blood of people who had SLE with the levels in
people who did not have the condition. Thirty people were recruited as
cases, from a group of patients with SLE who have been under
evaluation at Johns Hopkins School of Medicine since 1987. Fifteen
controls were recruited from a group of healthy people of similar age
and sex as the patients with SLE; everyone involved in the study gave
their consent to take part. Blood samples were taken from each
individual, and the serum (liquid component of blood) was separated
out. The serum levels of 160 different blood proteins were then
measured. When comparing levels of blood proteins between the
groups, the researchers found that 30 specific proteins were present at
higher or lower levels in the SLE-affected patients. Many of these
proteins are cytokines, which are regulated by interferons and are
involved in the process of ‘‘signaling’’ within the immune system. A few
proteins were found at lower levels. Levels of the interferon-regulated
proteins were, on average, seen at higher levels in people whose
condition was more severe.
What Do These Findings Mean? These results suggest that patients
with SLE are likely to have a very different pattern of regulation of certain
proteins within the blood, particularly the proteins involved in signaling
within the immune system. The authors propose that these proteins may
be involved in the progression of the disease. There is also the possibility
that some of these proteins may prove useful in diagnostic tests, or in
tests for monitoring how the disease progresses. However, before any
such tests could be used in clinical practice, they would need to be
further developed and then thoroughly tested in clinical trials.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030491
  Patient information from the UK National Health Service on systemic
lupus erythematosus
  Patient handout from the US National Institutes of Health
  MedlinePLUS encyclopedia entry on lupus
  Information on lupus from the UK Arthritis Research Campaign
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